A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout.
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2014
At a glance
- Drugs Arhalofenate (Primary)
- Indications Gout
- Focus Therapeutic Use
- Sponsors CymaBay Therapeutics
- 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 May 2011 New trial record